These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24914841)

  • 1. [Selection criteria and nomograms for active surveillance in prostate cáncer].
    Borque A; Esteban LM; Sanz G; Rubio-Briones J; Gil MJ
    Arch Esp Urol; 2014 Jun; 67(5):419-30. PubMed ID: 24914841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
    Reese AC; Landis P; Han M; Epstein JI; Carter HB
    J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contemporary concept of significant versus insignificant prostate cancer.
    Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
    Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
    Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
    J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostatectomy pathology findings in an active surveillance population.
    Ramirez-Backhaus M; Iborra I; Gomez-Ferrer A; Rubio-Briones J
    Arch Esp Urol; 2014 Jun; 67(5):431-9. PubMed ID: 24914842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.
    Venderbos LD; Roobol MJ; Bangma CH; van den Bergh RC; Bokhorst LP; Nieboer D; Godtman R; Hugosson J; van der Kwast T; Steyerberg EW
    World J Urol; 2016 Feb; 34(2):253-60. PubMed ID: 26160006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive report on prostate cancer misclassification by 16 currently used low-risk and active surveillance criteria.
    Palisaar JR; Noldus J; Löppenberg B; von Bodman C; Sommerer F; Eggert T
    BJU Int; 2012 Sep; 110(6 Pt B):E172-81. PubMed ID: 22314081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance.
    O'Brien BA; Cohen RJ; Ryan A; Sengupta S; Mills J
    J Urol; 2011 Nov; 186(5):1811-7. PubMed ID: 21944097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of prostate biopsy in patients considered for active surveillance. The role of the confirmatory biopsy and transperineal techniques.
    Fernandez Gomez JM; Garcia Rodriguez J
    Arch Esp Urol; 2014 Jun; 67(5):409-18. PubMed ID: 24914840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
    El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
    BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
    Dong F; Kattan MW; Steyerberg EW; Jones JS; Stephenson AJ; Schröder FH; Klein EA
    J Urol; 2008 Jul; 180(1):150-4; discussion 154. PubMed ID: 18485398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.
    Chun FK; Steuber T; Erbersdobler A; Currlin E; Walz J; Schlomm T; Haese A; Heinzer H; McCormack M; Huland H; Graefen M; Karakiewicz PI
    Eur Urol; 2006 May; 49(5):820-6. PubMed ID: 16439050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
    Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
    J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.